ethyl 4-(4-(4-fluorobenzoyl)piperidin-1-yl)butanoate | 1598371-28-8

• 英文名称: ethyl 4-(4-(4-fluorobenzoyl)piperidin-1-yl)butanoate
• 英文别名: Ethyl 4-[4-(4-fluorobenzoyl)piperidin-1-yl]butanoate
• CAS: 1598371-28-8
• 化学式: C₁₈H₂₄FNO₃
• 分子量: 321.392
• InChiKey: VXYVHAYSCHCHFT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  23
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  (4-(1-(4-ethoxy-4-oxobutyl)piperidine-4-carbonyl)phenyl)diphenylsulfonium trifluoromethanesulfonate 在 potassium fluoride 、 potassium hydrogencarbonate 、 4,7,13,16,21,24-六氧-1,10-二氮双环[8.8.8]二十六烷 作用下， 以 水 、 二甲基亚砜 、 乙腈 为溶剂， 反应 0.08h， 生成 ethyl 4-(4-(4-fluorobenzoyl)piperidin-1-yl)butanoate
  参考文献：
  名称：

  [EN] COMPOUNDS AND THEIR SYNTHESIS
  [FR] COMPOSÉS ET LEUR SYNTHÈSE

  摘要：

  本发明涉及公式（I）的磺隆盐：（I），它们的制备以及作为制备官能化有机化合物的前体的用途，其中R1和R2相同或不同，且每个都独立地选自可选取取代芳基基团，可选取取代炔基基团，可选取取代烯基基团，可选取取代烷基基团，可选取取代环烷基团，可选取取代环烯基基团，可选取取代芳基烷基基团，可选取取代芳基烯基基团，可选取取代杂芳基基团，可选取取代杂环基团，可选取取代胺基，可选取取代烷氧基，可选取取代硫醚基，可选取取代膦基，可选取取代硼物种，可选取取代卡宾，有机金属基团和卤素，或R1和R2结合形成可选取取代的含硫环；W是键，可选取取代的炔基亚基，可选取取代的烯基亚基，可选取取代的烷基亚基，可选取取代的杂环基团，可选取取代的芳基基团或可选取取代的杂芳基团；R3是包含至少一个碱性基团的基团，但当R3不含任何碳原子时，W不是键；X是阴离子物种；n是选自1至5的整数。

  公开号：

  WO2014057291A1

文献信息

• COMPOUNDS AND THEIR SYNTHESIS
  申请人：UCL BUSINESS PLC

  公开号：US20150266818A1

  公开（公告）日：2015-09-24

  The present invention relates to sulfonium salts of formula (I): (I), their preparation, and utility as precursors for preparing functionalised organic compounds, wherein R 1 and R 2 are the same or different and each is independently selected from an optionally substituted aryl group, an optionally substituted alkynyl group, an optionally substituted alkenyl group, an optionally substituted alkyl group, an optionally substituted cycloalkyl group, an optionally substituted cycloalkenyl group, an optionally substituted aralkyl group, an optionally substituted arylalkenyl group, an optionally substituted heteroaryl group, an optionally substituted heterocyclyl group, an optionally substituted amine, an optionally substituted alkoxy group, an optionally substituted thioether group, an optionally substituted phosphine group, an optionally substituted boron species, an optionally substituted carbene, an organometallic moiety, and a halide, or R 1 and R 2 are joined together to form an optionally substituted sulfur-containing ring; W is a bond, an optionally substituted alkynylene group, an optionally substituted alkenylene group, and optionally substituted alkylene group, an optionally substituted heterocyclyl group, an optionally substituted aryl group or an optionally substituted heteroaryl group; R 3 is a moiety comprising at least one basic group, provided that when R 3 does not contain any carbon atoms, W is not a bond; X is an anionic species; and n is an integer selected from 1 to 5.

  本发明涉及公式（I）的磺隆盐：（I），它们的制备以及作为制备官能化有机化合物的前体的用途，其中R1和R2相同或不同，且每个独立地选择自可选取的取代芳基基团，可选取的取代炔基基团，可选取的取代烯基基团，可选取的取代烷基基团，可选取的取代环烷基基团，可选取的取代环烯基基团，可选取的取代芳基烷基基团，可选取的取代芳基烯基基团，可选取的取代杂芳基基团，可选取的取代杂环基基团，可选取的取代胺基，可选取的取代烷氧基，可选取的取代硫醚基，可选取的取代膦基，可选取的取代硼物种，可选取的取代卡宾，有机金属基团以及卤素，或者R1和R2结合在一起形成可选取的含硫环；W是键，可选取的取代炔亚基基团，可选取的取代烯亚基基团，可选取的取代烷亚基基团，可选取的取代杂环基团，可选取的取代芳基基团或可选取的取代杂芳基基团；R3是含有至少一个碱性基团的基团，前提是当R3不含任何碳原子时，W不是键；X是一个阴离子物种；n是选自1到5的整数。
• Compounds and their synthesis
  申请人：UCL BUSINESS PLC

  公开号：US10118892B2

  公开（公告）日：2018-11-06

  The present invention relates to sulfonium salts of formula (I): (I), their preparation, and utility as precursors for preparing functionalized organic compounds, wherein R1 and R2 are the same or different and each is independently selected from an optionally substituted aryl group, an optionally substituted alkynyl group, an optionally substituted alkenyl group, an optionally substituted alkyl group, an optionally substituted cycloalkyl group, an optionally substituted cycloalkenyl group, an optionally substituted aralkyl group, an optionally substituted arylalkenyl group, an optionally substituted heteroaryl group, an optionally substituted heterocyclyl group, an optionally substituted amine, an optionally substituted alkoxy group, an optionally substituted thioether group, an optionally substituted phosphine group, an optionally substituted boron species, an optionally substituted carbene, an organometallic moiety, and a halide, or R1 and R2 are joined together to form an optionally substituted sulfur-containing ring; W is a bond, an optionally substituted alkynylene group, an optionally substituted alkenylene group, and optionally substituted alkylene group, an optionally substituted heterocyclyl group, an optionally substituted aryl group or an optionally substituted heteroaryl group; R3 is a moiety comprising at least one basic group, provided that when R3 does not contain any carbon atoms, W is not a bond; X is an anionic species; and n is an integer selected from 1 to 5.

  本发明涉及式(I)的锍盐：(其中 R1 和 R2 相同或不同，且各自独立选自任选取代的芳基、任选取代的炔基、任选取代的烯基、任选取代的烷基、任选取代的环烷基、任选取代的环烯基、任选取代的芳烷基任选取代的芳烷基、任选取代的杂芳基、任选取代的杂环基、任选取代的胺、任选取代的烷氧基、任选取代的硫醚基、任选取代的膦基、任选取代的硼种、任选取代的碳、有机金属分子和卤化物，或 R1 和 R2 连接在一起形成任选取代的含硫环；W 是键、任选取代的炔基团、任选取代的烯基团、任选取代的亚烷基团、任选取代的杂环基团、任选取代的芳基团或任选取代的杂芳基团；R3 是包含至少一个碱性基团的分子，但当 R3 不包含任何碳原子时，W 不是键；X 是阴离子物种；以及 n 是选自 1 至 5 的整数。
• Development of Fluorine-18 Labeled Metabolically Activated Tracers for Imaging of Drug Efflux Transporters with Positron Emission Tomography
  作者：Kerstin Sander、Eva Galante、Thibault Gendron、Elena Yiannaki、Niral Patel、Tammy L. Kalber、Adam Badar、Mathew Robson、Sean P. Johnson、Florian Bauer、Severin Mairinger、Johann Stanek、Thomas Wanek、Claudia Kuntner、Tim Kottke、Lilia Weizel、David Dickens、Kjell Erlandsson、Brian F. Hutton、Mark F. Lythgoe、Holger Stark、Oliver Langer、Matthias Koepp、Erik Årstad

  DOI：10.1021/acs.jmedchem.5b00652

  日期：2015.8.13

  Increased activity of efflux transporters, e.g., P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), at the blood brain barrier is a pathological hallmark of many neurological diseases, and the resulting multiple drug resistance represents a major clinical challenge. Noninvasive imaging of transporter activity can help to clarify the underlying mechanisms of drug resistance and facilitate diagnosis, patient stratification, and treatment monitoring. We have developed a metabolically activated radiotracer for functional imaging of P-gp/BCRP activity with positron emission tomography (PET). In preclinical studies, the tracer showed excellent initial brain uptake and clean conversion to the desired metabolite, although at a sluggish rate. Blocking with P-gp/BCRP modulators led to increased levels of brain radioactivity; however, dynamic PET did not show differential clearance rates between treatment and control groups. Our results provide proof-of-concept for development of prodrug tracers for imaging of P- /BCRP function in vivo but also highlight some challenges associated with this strategy.